According to the company, effective January 1, 2025, cyclosporine ophthalmic solution 0.1% (Vevye) will be included on key ...

田纳西州纳什维尔 - 北美知名眼科制药公司Harrow (NASDAQ:HROW)宣布，其干眼症治疗药物VEVYE将从2025年1月1日起被纳入2025年医疗保险D部分处方药计划。这项药物被纳入Express Scripts、Cigna、Kaiser Permanente和CVS Caremark等主要计划赞助商的处方药目录，使VEVYE的覆盖范围扩大到超过2500万医疗保险D部分受益人。

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access ...

agreed to pay the state of Illinois $57 million a few years back to settle an investigation into alleged overbilling of ...

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price target was ...

Cold water has been tossed on the idea that CVS Health would break up the company and sell off health or pharmacy benefits from assets that provide medical care. In his first earnings call following a ...

This story was originally published by KFF Health News. While customers at Adams Family Pharmacy picked up their ...

6, posted revenue growth of 36 percent and 37 percent, respectively, during the third quarter compared to a year earlier.

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

The Rio-based network of independent pharmacies blames drug industry intermediaries known as pharmacy benefit managers.

A former chief executive officer at UnitedHealthcare has been selected to serve as the president of CVS Health's Aetna insurance subsidiary. David Joyner, president and chief executive officer of CVS ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...